<DOC>
	<DOCNO>NCT00540839</DOCNO>
	<brief_summary>A study determine effect montelukast ( MK-0476 ) pediatric participant chronic asthma compare fluticasone . The primary hypothesis , 24 week treatment , montelukast provide least level asthma control inhale fluticasone measure percentage day without asthma , 24 week treatment , daily administration montelukast safe well tolerated child age 6 month 5 year chronic asthma . This trial stop time participant actually enter trial . Based input regulatory agency , necessary conduct study ; separate ongoing study sufficient regulatory purpose .</brief_summary>
	<brief_title>A Study Montelukast ( MK-0476 ) Compared With Fluticasone Pediatric Participants With Chronic Asthma ( MK-0476-303 )</brief_title>
	<detailed_description>This study consist 4-week placebo run-in period follow 24-week double-blind treatment period .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Between 6 month 5 year , 4 month age Diagnosed asthma doctor At least 3 episode asthma symptom within last 6 month Active chronic breathing disease , asthma Required insertion breathe tube asthma Major surgery within last 4 week Currently hospital Allergic certain drug , child 2 year age , apple , applesauce formula</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>